24/7 Wall Street
16 Jul 2026, 11:40 UTC · 1h ago
What Investors Don't Understand About Abbott Laboratories
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
24/7 Wall Street
16 Jul 2026, 11:40 UTC · 1h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
4 claims · each scored for market impact
Abbott completed a $21 billion acquisition of Exact Sciences, expected to generate approximately $3 billion in incremental sales in 2026. — Significant inorganic growth through a major acquisition typically boosts long-term revenue projections and expands market share in diagnostics.
+0.60CEO Robert Ford projects the global continuous glucose monitor (CGM) market will expand from 10-12 million current users to 70-80 million. — A massive projected increase in the Total Addressable Market (TAM) for a core growth engine suggests significant long-term upside.
+0.50Abbott shares are trading approximately 29% below the analyst consensus buy target and 32.1% lower over one year despite four consecutive EPS beats. — A strong disconnect between fundamental performance (EPS beats) and price action suggests the stock may be undervalued.
+0.40Continue reading
6 related stories
Top 3 movers · tap to explore
The Nutrition segment revenue fell 6.0% to $2.02 billion, reflecting a decline in a core legacy business area. — Revenue declines in a key segment create a drag on overall growth and maintain negative sentiment among some investors.
-0.20Which stocks this story touches
The company has posted four consecutive EPS beats, strong growth in medical devices, and a strategic acquisition of Exact Sciences.
Mentioned as a competitive threat to Abbott's continuous glucose monitoring market share.
Mentioned only as a benchmark global giant in the context of a sponsored ad.
[a_to_b] Abbott closed a $21 billion acquisition of Exact Sciences.
[b_to_a] Exact Sciences became a subsidiary of Abbott following the acquisition.
[mutual] Both companies compete in the continuous glucose monitoring (CGM) market.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
Invezz
20m ago
